Gujarat Kidney And Super Speciality Limited (GKSL) — deviation variation
The Monitoring Agency Report confirms that Gujarat Kidney and Super Speciality Limited raised ₹250.80 crores through a fresh equity issue and utilized funds for specific hospital acquisitions and inorganic growth, with no material deviation from stated objects. The report verifies compliance with SEBI ICDR Regulations and confirms all statutory approvals were obtained.
About Gujarat Kidney And Super Speciality Limited (GKSL)
Healthcare · Healthcare Services · Listed on NSE
📡 Get AI alerts when GKSL files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track GKSL — Free💡 Ask AI about this filing
📊 More GKSL filings
- Financial Results — 10 July 2026 Gujarat Kidney and Super Speciality Limited clarified a typographical error in the signing date of i...
- 🟡 Board Meeting — 9 July 2026 Gujarat Kidney and Super Speciality Limited announced on July 9, 2026, that its board approved a 51%...
- 🟡 Board Meeting — 9 July 2026 GKSL's board approved a 51% stake purchase in UAE's Blue Tree Clinics LLC via cash consideration of ...
- 🟡 Voting Results — 6 July 2026 No summary available
- Financial Results — 26 June 2026 Gujarat Kidney And Super Speciality Limited announced that its trading window will close on 1st July...
🔥 Also filed on 15 May 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when GKSL files new disclosures
Track GKSL filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track GKSL — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research